- November 12, 2025
- Posted by: admin
- Category: Blog
The pharmaceutical industry in Turkey has developed into a dynamic, well-regulated, and innovation-driven ecosystem that bridges Europe and Asia. For international investors and manufacturers, understanding the drug registration in Turkey process is crucial for compliance, efficiency, and market access. The Turkish Medicines and Medical Devices Agency (TİTCK) governs this complex but transparent framework, ensuring that every medicinal product entering the Turkish market meets rigorous safety, efficacy, and quality standards.
This article provides an in-depth exploration of the Turkish regulatory pathways for drug registration in Turkey, including pre-submission requirements, dossier formats, good manufacturing practice (GMP) certification, and post-marketing obligations. It is structured as a topic-cluster cornerstone, connecting regulatory, investment, and operational aspects within Turkey’s pharmaceutical landscape.
Overview of the Turkish Pharmaceutical Regulatory Framework
The Republic of Turkey regulates all human medicinal products under the authority of TİTCK (Türkiye İlaç ve Tıbbi Cihaz Kurumu), operating under the Ministry of Health. The current framework aligns closely with the European Union’s directives, reflecting Turkey’s integration into the global regulatory community.
Key Legislative Foundations
The principal legal instruments that shape pharmaceutical regulation in Turkey include:
- Regulation on Licensing of Human Medicinal Products (2011)
- Regulation on Manufacturing Sites and GMP Requirements (2010)
- Decree Law No. 663 on the Organization and Duties of the Ministry of Health
- Regulation on Promotional Activities of Medicinal Products
These legal foundations ensure that Turkey’s licensing and marketing authorization procedures are harmonized with EU standards, especially concerning dossier preparation, pharmacovigilance, and GMP audits.
Role of the Turkish Medicines and Medical Devices Agency (TİTCK)
The TİTCK is the national authority responsible for evaluating, approving, and monitoring pharmaceuticals in Turkey. Its core responsibilities include:
- Assessing marketing authorization applications
- Conducting GMP inspections for both domestic and foreign manufacturing sites
- Evaluating clinical trial applications
- Overseeing pharmacovigilance and safety reporting systems
The agency is known for its digital submission infrastructure (via e-Başvuru portal), which streamlines documentation and increases transparency.
Official information can be verified directly at https://www.titck.gov.tr.
The Marketing Authorization Process in Turkey
Step 1: Determining the Product Classification
Before initiating the registration process, applicants must classify their product correctly. TİTCK distinguishes between:
- Human medicinal products (chemical, biological, or biosimilar)
- Herbal medicinal products
- Radiopharmaceuticals
- Traditional herbal medicinal products (THMPs)
The classification affects dossier requirements, labeling, and post-market surveillance obligations.
Step 2: Preparing the Dossier in CTD Format
Turkey mandates the Common Technical Document (CTD) format, consistent with the International Council for Harmonisation (ICH) standards. The five modules are:
- Administrative Information and Product Data
- Summary Documents
- Quality (Chemical, Pharmaceutical, and Biological Information)
- Non-Clinical Study Reports
- Clinical Study Reports
All modules must be submitted in Turkish or accompanied by certified translation services in Turkey that ensure linguistic and regulatory accuracy.
Step 3: GMP Certification
A critical step before dossier submission is obtaining GMP certification for the manufacturing site. TİTCK inspectors visit the production facilities (both domestic and abroad) to verify compliance with Turkish and EU GMP standards. The inspection results are decisive — a deficiency may delay approval significantly.
For foreign investors planning to establish their own manufacturing line, our detailed guide on How to Set Up a Pharmaceutical Company in Turkey: Legal & Regulatory Guide for Foreign Investors provides an overview of licensing procedures, incentives, and compliance obligations.
Application Pathways for Drug Registration in Turkey
The TİTCK offers several pathways for product authorization, each suited to different product profiles and data availability.
1. Full Dossier (Standard Application)
This route applies to new chemical entities or original products supported by complete clinical and non-clinical data. Applicants must present comprehensive CTD documentation and pharmacovigilance risk management plans.
2. Abridged Application
For products already authorized within the EU or ICH region, Turkey allows an abridged application, relying on reference evaluations from recognized regulatory bodies. Still, the applicant must adapt the data to local requirements, including Turkish labeling and patient information leaflets.
3. Generic Application
If a reference product has already been authorized in Turkey, applicants may pursue a generic application demonstrating bioequivalence instead of full clinical data. Bioavailability studies must be conducted in accredited centers approved by the TİTCK.
4. Biosimilar Application
Given the growing significance of biopharmaceuticals, biosimilar products undergo comparative analytical and clinical assessments to prove similarity in efficacy and safety to the reference biological product.
5. Traditional Herbal and Homeopathic Products
Products derived from herbal or natural sources follow a distinct regulatory pathway. For investors exploring this sector, our comprehensive resource Investing in Herbal Supplement Production in Turkey: A Growing Opportunity for Foreign Entrepreneurs provides insights into market dynamics and registration nuances.
Evaluation Timeline and Decision Making
The TİTCK commits to specific evaluation periods:
- Administrative review: 30 days
- Technical assessment: 210 days (may extend if deficiencies are found)
- Decision notification: within 15 days after completion of assessment
In practice, well-prepared applications that fulfill GMP, translation, and documentation standards can achieve authorization within 8–12 months.
Post-Authorization Requirements
Pharmacovigilance and Risk Management
Once a marketing authorization is granted, the MAH (Marketing Authorization Holder) must maintain a pharmacovigilance system managed by a Qualified Person for Pharmacovigilance (QPPV) based in Turkey. The QPPV ensures continuous safety data collection, signal detection, and submission of periodic safety update reports (PSURs).
Variations and Renewals
Marketing authorizations are initially valid for five years and must be renewed based on post-marketing safety evaluations. Any variation — such as formulation changes, packaging updates, or manufacturing site transfers — must be approved by the TİTCK before implementation.
Pricing, Reimbursement, and Market Access
Obtaining marketing authorization is only the first step. To commercialize a product in Turkey, companies must also navigate pricing and reimbursement frameworks.
- Pricing: Determined by the Ministry of Health Price Evaluation Commission, referencing EU pricing data and exchange rates.
- Reimbursement: Managed by the Social Security Institution (SGK), which decides on coverage inclusion and reimbursement limits.
These economic controls ensure patient access while maintaining fiscal sustainability.
For further information, the SGK’s official portal (https://www.sgk.gov.tr) offers updated reimbursement lists and public price decrees.
Intellectual Property and Data Exclusivity
The protection of proprietary data and intellectual property is crucial in Turkey’s pharmaceutical sector. Patent protection lasts 20 years from the filing date, and data exclusivity for new chemical entities is granted for six years, during which no generic applications can rely on the original dossier.
Turkey is a member of the World Intellectual Property Organization (WIPO) and a signatory to the TRIPS Agreement, ensuring international IP compliance. Detailed patent search tools are available through the Turkish Patent and Trademark Office.
Regulatory Alignment with the European Union
Although Turkey is not an EU member, its regulatory framework mirrors EU pharmaceutical directives. This alignment benefits multinational companies seeking simultaneous submissions across both regions. Harmonization efforts include:
- Implementation of ICH and EMA guidelines
- Standardization of GMP inspection procedures
- Electronic submission compatibility through eCTD
Such integration promotes trust in Turkish regulatory decisions and simplifies regional market expansion.
Establishing a Pharmaceutical Business Entity in Turkey
Foreign investors interested in entering the Turkish pharmaceutical market must establish a legal presence — typically a limited liability company or joint-stock company. Detailed information about incorporation, tax, and operational setup is covered in our guides:
Legal support from an English speaking lawyer in Turkey ensures compliance with company law, pharmaceutical licensing, and Ministry of Health correspondence.
Taxation and Financial Compliance for Pharmaceutical Companies
Pharmaceutical entities must comply with general corporate tax obligations. Key fiscal topics include:
- Value-Added Tax (VAT): Applied at various rates, with exemptions for some medicinal products. See Vat in Turkey.
- Corporate Income Tax: 25% (as of 2025) on net profits.
- Taxpayer Obligations: Clarified in Tax Payers in Turkey.
Incentive programs such as Technological Development Zones (TGBs) and R&D deductions reduce the effective tax burden for pharmaceutical innovators.
Challenges and Opportunities in the Turkish Drug Market
While the regulatory pathway is robust, applicants may encounter challenges such as:
- Language barriers during dossier preparation
- Delays in GMP inspection scheduling
- Exchange rate fluctuations affecting pricing
- Complex reimbursement negotiations
Nevertheless, Turkey offers significant opportunities — a population of over 85 million, a rapidly expanding healthcare infrastructure, and strategic access to EMEA markets.
Moreover, government initiatives like the 11th Development Plan and National Medicine and Medical Device Strategy aim to increase local production and R&D capacity, particularly in biotechnology and vaccine manufacturing.
Future Outlook: Digitalization and Global Integration
TİTCK’s ongoing digitalization agenda includes e-pharmacovigilance, blockchain traceability systems, and AI-assisted dossier screening. These technologies enhance transparency and reduce administrative delays. Additionally, Turkey’s participation in global harmonization programs ensures sustained alignment with EMA and WHO standards.
The drug registration in Turkey process is expected to become faster and more predictable through such reforms, positioning Turkey as a regional hub for pharmaceutical production and regulatory excellence.
Conclusion
Navigating Turkey’s regulatory landscape requires strategic foresight, legal precision, and technical expertise. From GMP certification to post-market vigilance, the system is comprehensive but rewarding for compliant and quality-driven firms. Whether you aim to license, manufacture, or distribute medicines, Turkey offers a fertile environment supported by strong governance and international alignment.
To ensure successful market entry and regulatory compliance, foreign investors are encouraged to partner with experienced legal and regulatory consultants. FO-Consultancy specializes in end-to-end guidance — from company setup and licensing to documentation, translation, and tax optimization , drug registration in Turkey— ensuring a smooth and compliant journey into one of the most promising pharmaceutical markets in the world.
